Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions

Cancer Letters

Volumn 295, Issue 2, 2010, Pages 173-181

  Schmudde, Mareike ^a   Friebe, Erika ^a   Sonnemann, Jürgen ^b   Beck, James F ^b   Bröker, Barbara M ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Cytotoxicity; Histone deacetylase inhibitors; NK activation; Priming; SAHA

Indexed keywords

INTERLEUKIN 2; VORINOSTAT;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANTIGENS, CD86; APOPTOSIS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MITOMYCIN; T-LYMPHOCYTES;

EID: 77954027739     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.02.024     Document Type: Article

References (38)

1. Kelly W.K., Marks P.A. Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. 2005, 2:150-157.
2. Glaser K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol. 2007, 74:659-671.
3. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
4. Marks P.A., Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 2007, 25:84-90.
5. Peart M.J., Smyth G.K., van Laar R.K., Bowtell D.D., Richon V.M., Marks P.A., Holloway A.J., Johnstone R.W. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 2005, 102:3697-3702.
6. Spange S., Wagner T., Heinzel T., Kramer O.H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 2009, 41:185-198.
7. Nolan L., Johnson P.W., Ganesan A., Packham G., Crabb S.J. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?. Br. J. Cancer 2008, 99:689-694.
8. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008, 269:7-17.
9. Schmudde M., Braun A., Pende D., Sonnemann J., Klier U., Beck J.F., Moretta L., Broker B.M. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett. 2008.
10. Armeanu S., Bitzer M., Lauer U.M., Venturelli S., Pathil A., Krusch M., Kaiser S., Jobst J., Smirnow I., Wagner A., Steinle A., Salih H.R. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005, 65:6321-6329.
11. Skov S., Pedersen M.T., Andresen L., Straten P.T., Woetmann A., Ødum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005, 65:11136-11145.
12. Zang X., Allison J.P. The B7 family and cancer therapy: costimulation and coinhibition. Clin. Cancer Res. 2007, 13:5271-5279.
13. Rudy W., Gückel B., Siebels M., Lindauer M., Meuer S.C., Moebius U. Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-g. Int. Immunol. 1997, 9:853-860.
14. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Iyer N.G., Pérez-Rosado A., Calvo E., Lopez J.A., Cano A., Calasanz M.J., Colomer D., Piris M.A., Ahn N., Imhof A., Caldas C., Jenuwein T., Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
15. Atadja P., Gao L., Kwon P., Trogani N., Walker H., Hsu M., Yeleswarapu L., Chandramouli N., Perez L., Versace R., Wu A., Sambucetti L., Lassota P., Cohen D., Bair K., Wood A., Remiszewski S. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004, 64:689-695.
16. Ungerstedt J.S., Sowa Y., Xu W.S., Shao Y., Dokmanovic M., Perez G., Ngo L., Holmgren A., Jiang X., Marks P.A. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 2005, 102:673-678.
17. Zou Y.R., Sunshine M.J., Taniuchi I., Hatam F., Killeen N., Littman D.R. Epigenetic silencing of CD4 in T cells committed to the cytotoxic lineage. Nat. Genet. 2001, 29:332-336.
18. Avni O., Lee D., Macian F., Szabo S.J., Glimcher L.H., Rao A. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat. Immunol. 2002, 3:643-651.
19. Skov S., Rieneck K., Bovin L.F., Skak K., Tomra S., Michelsen B.K., Ødum N. Histone deacetylase inhibitors: a new class of immuno suppressors targeting a novel signal pathway essential for CD154 expression. Blood 2003, 101:1430-1438.
20. Moreira J.M.A., Scheipers P., Sørensen P. The histone deacetylase inhibitor trichostatin A modulates CD4+ T cell responses. BMC Cancer 2003, 3:30.
21. Leoni F., Fossati G., Lewis E.C., Lee J.-K., Porro G., Pagani P., Modena D., Moras M.L., Pozzi P., Reznikov L.L., Siegmund B., Fantuzzi G., Dinarello C.A., Mascagni P. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 2005, 11:1-15.
22. Tao R., de Zoeten E.F., Ozkaynak E., Wang L., Li B., Greene M.I., Wells A.D., Hancock W.W. Histone deacetylase inhibitors and transplantation. Curr. Opin. Immunol. 2007, 19:589-595.
23. Reddy P., Maeda Y., Hotary K., Liu C., Reznikov L.L., Dinarello C.A., Ferrara J.L.M. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. PNAS 2004, 101:3921-3926.
24. Chou T.-C. Theoretical basis experimental design and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
25. Ogbomo H., Michaelis M., Kreuter J., Doerr H.W., Cinatl J. Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett. 2007, 581:1317-1322.
26. Taplik J., Kurtev V., Lagger G., Seiser C. Histone H4 acetylation during interleukin-2 stimulation of mouse T cells. FEBS Lett. 1998, 436:349-352.
27. Cichocki F., Hanson R.J., Lenvik T., Pitt M., McCullar V., Li H., Anderson S.K., Miller J.S. The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element. Blood 2009.
28. Griffiths G.M. The cell biology of CTL killing. Curr. Opin. Immunol. 1995, 7:343-348.
29. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., Li B., Turka L.A., Olson E.N., Greene M.I., Wells A.D., Hancock W.W. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 2007, 13:1299-1307.
30. + regulatory T cells in rhesus macaques. Transplant. Proc. 2008, 40:459-461.
31. Serrador J.M., Cabrero J.R., Sancho D., Mittelbrunn M., Urzainqui A., Sánchez-Madrid F. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity 2004, 20:417-428.
32. Villagra A., Cheng F., Wang H.-W., Suarez I., Glozak M., Maurin M., Nguyen D., Wright K.L., Atadja P.W., Bhalla K., Pinilla-Ibarz J., Seto E., Sotomayor E.M. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol. 2009, 10:92-100.
33. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729.
34. Vivier E., Tomasello E., Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition?. Curr. Opin. Immunol. 2002, 14:306-311.
35. Weiser T.S., Guo Z.S., Ohnmacht G.A., Parkhurst M.L., Tong-On P., Marincola F.M., Fischette M.R., Yu X., Chen G.A., Hong J.A., Stewart J.H., Nguyen D.M., Rosenberg S.A., Schrump D.S. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother. 2001, 24:151-161.
36. Pellicciotta I., Cortez-Gonzalez X., Sasik R., Reiter Y., Hardiman G., Langlade-Demoyen P., Zanetti M. Presentation of telomerase reverse transcriptase, a self-tumor antigen, is down-regulated by histone deacetylase inhibition. Cancer Res. 2008, 68:8085-8093.
37. Kobayashi K., Hatano M., Otaki M., Ogasawara T., Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc. Natl. Acad. Sci. USA 1999, 96:1457-1462.
38. Sharief M.K., Semra Y.K. Upregulation of the inhibitor of apoptosis proteins in activated T lymphocytes from patients with multiple sclerosis. J. Neuroimmunol. 2001, 119:350-357.